1. “Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis”
by Alessandro Rizzo, Antonio Cusmai, Francesco Giovannelli, Silvana Acquafredda, Lucia Rinaldi, Andrea Misino, Elisabetta Sara Montagna, Valentina Ungaro, Mariagrazia Lorusso and Gennaro Palmiotti
Cancers 2022, 14(6), 1404; https://doi.org/10.3390/cancers14061404
Available online: https://www.mdpi.com/2072-6694/14/6/1404

2. “The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions”
by Tadeusz Robak, Magda Witkowska and Piotr Smolewski
Cancers 2022, 14(3), 771; https://doi.org/10.3390/cancers14030771
Available online: https://www.mdpi.com/2072-6694/14/3/771

3. “The Good, the Bad, and the Ugly: Neutrophils, Angiogenesis, and Cancer”
by Irem Ozel, Inga Duerig, Maksim Domnich, Stephan Lang, Ekaterina Pylaeva and Jadwiga Jablonska
Cancers 2022, 14(3), 536; https://doi.org/10.3390/cancers14030536
Available online: https://www.mdpi.com/2072-6694/14/3/536

4. “Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study”
by Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Seong Gyu Hwang, Young Eun Chon and Hong Jae Chon
Cancers 2022, 14(7), 1747; https://doi.org/10.3390/cancers14071747
Available online: https://www.mdpi.com/2072-6694/14/7/1747

5. “Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer”
by Ching-Hung Hsieh, Cheng-Zhe Jian, Liang-In Lin, Guan-Sian Low, Ping-Yun Ou, Chiun Hsu and Da-Liang Ou
Cancers 2022, 14(2), 294; https://doi.org/10.3390/cancers14020294
Available online: https://www.mdpi.com/2072-6694/14/2/294

6. “Clinical Significance of the Duality of Wnt/β-Catenin Signaling in Human Hepatocellular Carcinoma”
by Tomoko Aoki, Naoshi Nishida and Masatoshi Kudo
Cancers 2022, 14(2), 444; https://doi.org/10.3390/cancers14020444
Available online: https://www.mdpi.com/2072-6694/14/2/444

by Biagio Barone, Armando Calogero, Luca Scafuri, Matteo Ferro, Giuseppe Lucarelli, Erika Di Zazzo, Enrico Sicignano, Alfonso Falcone, Lorenzo Romano, Luigi De Luca et al.
Cancers 2022, 14(10), 2545; https://doi.org/10.3390/cancers14102545
Available online: https://www.mdpi.com/2072-6694/14/10/2545

8. “Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine”
by Nicolas Huyghe, Elena Benidovskaya, Philippe Stevens and Marc Van den Eynde
Cancers 2022, 14(9), 2241; https://doi.org/10.3390/cancers14092241
Available online: https://www.mdpi.com/2072-6694/14/9/2241

9. “Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes”
by Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco et al.
Cancers 2022, 14(10), 2429; https://doi.org/10.3390/cancers14102429
Available online: https://www.mdpi.com/2072-6694/14/10/2429

10. “Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities”
by Carmelo Laface, Palma Fedele, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Pasquale Molinari, Michele Ammendola, Marco Lioce and Girolamo Ranieri
Cancers 2022, 14(16), 4028; https://doi.org/10.3390/cancers14164028
Available online: https://www.mdpi.com/2072-6694/14/16/4028